InMed was founded to advance drug programs for epidermolysis bullosa [EB], a skin condition that results in layers of skin not sticking to each other and for glaucoma, an eye condition that damages the optic nerve. Read More
IPO Launch: InMed Pharmaceuticals Finalizes Uplisting / IPO Plan
2024-06-13T00:36:36-04:00June 13th, 2024|
Related Posts
-
Complete Circle: Biosecure Act could boost Indian biotechnology
September 9th, 2024 -
Events.com to go public via SPAC deal
August 29th, 2024 -
Pershing Square postpones U.S. closed-end fund IPO
July 26th, 2024